PDL-1 22C3 Dako

PD-L1 Dako 22C3 is a diagnostic assay that is a protein expressed on certain cells, including cancer cells, which can suppress immune responses. The Dako 22C3 assay is used in conjunction with specific medicines like pembrolizumab (Keytruda), an immunotherapy drug that targets PD-1/PD-L1 interaction. By assessing the PD-L1 expression level, the assay helps identify patients who may benefit from pembrolizumab treatment. High PD-L1 expression suggests a greater likelihood of response to immunotherapy.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.